# Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review

## TL;DR

This paper reviews current pharmacotherapies for drug-induced liver injury and highlights treatment options and research gaps.

## Contribution

The paper systematically categorizes and evaluates existing drug treatments for DILI based on clinical evidence.

## Key findings

- Hepatoprotective drugs like N-acetylcysteine and Silymarin are commonly used for DILI.
- Anticholestatic and immunosuppressant drugs are also part of the treatment regimen.
- The review identifies unmet needs and limitations in current clinical studies on DILI therapies.

## Abstract

Drug-induced liver injury (DILI) has become a serious public health problem. For the management of DILI, discontinuation of suspicious drug or medicine is the first step, but the treatments including drugs and supporting approaches are needed. Reference to clinical patterns and disease severity grades of DILI, the treatment drugs were considered to summarize into hepatoprotective drugs (N-acetylcysteine and Glutathione, Glycyrrhizin acid preparation, Polyene phosphatidylcholine, Bicyclol, Silymarin), anticholestatic drug (Ursodeoxycholic acid, S-adenosylmethionine, Cholestyramine), immunosuppressants (Glucocorticoids) and specific treatment agents (L-carnitine, Anticoagulants). The current article reviewed the accumulated literature with evidence-based medicine researches for DILI in clinical practice. Also the drawbacks of the clinical studies involved in the article, unmet needs and prospective development for DILI therapy were discussed.